MAT2A and acute myeloid leukemia: Our findings underscore the innovative approach of combining VEN with the RNA-directed anti-cancer compounds 8CA/8AA (VEN + 8CA; VEN + 8AA) for AML treatment by targeting the methionine-MAT2A-SAM axis [10, 12, 13, 35].